<DOC>
	<DOCNO>NCT01216514</DOCNO>
	<brief_summary>Factors forecast Chronic Inflammatory Bowel Diseases ( IBD ) remain present essentially clinical factor ( extension disease , achievement perianal ring , requirement surgery , treatment immunomodulatorsâ€¦ ) . All IBD specific immunological serological marker show diagnostic role indefinite colitis ( hemorrhagic Rectocolitis v Crohn Disease ) never able consider predictive element adult IBD evolution . Among used , presence ANCA 's antibody ASCA allow separate hemorrhagic rectocolitis ( ANCA + / ASCA- ) Crohn disease ( ANCA-/ASCA + ) combination present average sensibility 85 % 85 % specificity . However , 8 antibody type recently isolate estimate individually IBD particular child Crohn diseases ( anti-OmpC , anti-I2 , anti-CBir1 , anti-glycans ( ALCA , AMCA ACCA ) anti-Goblet cell albicans Candida 's specific anti-mannan ) . These complementary assay improve significantly reliability diagnosis . However , use new marker indisputable diagnostic role , predictive role evolution IBD estimate adult 's rarely Crohn disease . Consequently , investigator suggest realize exhaustive analysis new immunological marker define , association interest differentiation stable ( little evolutionary ) unstable ( quickly evolutionary ) clinical form .</brief_summary>
	<brief_title>Serologic Markers Inflammatory Bowel Disease During Clinical Forms With Weak Strong Evolution Capacities</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Major Patient IBD ( RCH MC ) diagnose accord clinical , endoscopic histological criterion Accepting sample blood Patient member legal successor national insurance scheme Taken care medical service gastroenterology CHU de Saint Etienne Patient sign form consent Minor Patient uncapable Patient suffer indefinite colitis Refusal sample blood Pregnant Woman Incapacity refusal sign consent write Subjects deprive freedom court administrative order Use antiTNF . According indication ensue Sonic trial strategy `` Top Down `` .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>chronic inflammatory bowel disease</keyword>
	<keyword>crohn disease</keyword>
	<keyword>hemorrhagic rectocolitis</keyword>
	<keyword>immunological marker</keyword>
	<keyword>serological marker</keyword>
	<keyword>ANCA</keyword>
	<keyword>ASCA</keyword>
</DOC>